Interaction of macrolides with alpha dornase during DNA hydrolysis.
Since patients with cystic fibrosis are often treated with alpha dornase to reduce sputum viscosity, and because of preliminary reports of efficacy of long-term low-dose erythromycin therapy in chronic airway diseases, it is likely that alpha dornase and macrolides might be given together in such patients. A possible interaction between these drugs was therefore investigated. Using hyperchromic effect to quantify alpha dornase activity, a time- and dose-dependent inhibitory effect on human DNA hydrolysis has been observed for erythromycin, roxithromycin and azithromycin. Inhibitory doses 50% for alpha dornase were graphically determined. Azithromycin exhibited the strongest inhibitory effect.
Ripoll
L
L
Laboratoire de Microbiologie, Hôpital Saint-Louis, Paris, France.
Reinert
P
P
Pépin
L F
LF
Lagrange
P H
PH
D017963:Azithromycin / Q000494:pharmacology*; D004247:DNA / Q000187:drug effects / Q000378:metabolism*; D003850:Deoxyribonuclease I / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology*; D006801:Humans; D006868:Hydrolysis; D007700:Kinetics; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D015575:Roxithromycin / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D011994:Recombinant Proteins; D015575:Roxithromycin; D004917:Erythromycin; D017963:Azithromycin; D004247:DNA; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I